Accuray Appoints Paul Miele as Chief Commercial Officer for Continued Growth

Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer

On April 6, 2026, Accuray Incorporated, a prominent provider of radiation therapy systems designed for cancer treatment, revealed the appointment of Paul Miele as the new Senior Vice President and Chief Commercial Officer. This strategic move aims to bolster the company’s global commercial organization as it embarks on significant transformations to enhance its operational execution across a diversified portfolio.

Steve La Neve, Accuray's President and Chief Executive Officer, expressed optimism regarding Miele's extensive experience, noting his impressive background that spans nearly two decades leading and developing global capital medical device businesses in regions including the Americas, EMEA, and APAC. Miele's previous success as Business Unit Leader and General Manager for the MONARCH™ robotic platform at Johnson & Johnson MedTech exemplifies his capability in driving commercial turnarounds. His leadership there contributed to robust double-digit percentage annual sales growth, reversing previously declining revenue trends.

Miele's responsibilities at Accuray will encompass defining and executing the company's overall commercialization strategy. This includes management of sales, marketing, pricing strategies, and market access efforts, while fostering valuable commercial partnerships. This direction is especially crucial as Accuray seeks to further solidify its role within the healthcare market, focusing heavily on delivering groundbreaking solutions for cancer treatment in over 70 countries worldwide.

A Vision for Innovation and Growth

As Miele prepares to join the executive leadership team, he acknowledged the strengths that Accuray possesses. "Accuray has a strong foundation of innovation, a vast installed base, and dedicated distribution partners. I see a significant opportunity to leverage these strengths to amplify our commercial impact on the global stage," he stated. Miele’s vision emphasizes the importance of providing value-added solutions that can meet the diverse needs of healthcare providers and, ultimately, patients facing cancer treatment.

Accuray has always prioritized delivering tailored radiation treatment solutions, pushing the envelope in both innovative designs and practical applications. By continuing to advance its product offerings and aligning them with the ever-changing healthcare landscape, the company aims to support clinicians in providing the best care possible to patients.

About Accuray Incorporated

Accuray Incorporated (NASDAQ: ARAY) stands at the forefront of innovative radiation therapy, committed to improving patient lives through its cutting-edge technologies. The company focuses on creating market-changing solutions that make complex cases more manageable and common cases even easier to treat. With a mission driven by continuous innovation and a deep understanding of clinical needs, Accuray collaborates closely with healthcare professionals around the world.

While navigating a highly competitive and rapidly evolving field, the company's focus on operational excellence is evident in its strategic appointment of leaders like Paul Miele. This new chapter is not just about enhancing sales but involves a broader narrative of fostering lasting relationships and ensuring sustainable growth. The successful execution of a comprehensive commercialization strategy could significantly contribute to not only the company’s financial performance but also to its long-term value creation.

This appointment reinforces Accuray's commitment to redefining standards in cancer treatment through ongoing advancements in technology and quality. As they move forward, the company's stakeholders can expect a deeper engagement in the marketplace, along with enhanced efforts to fulfill the needs of healthcare practitioners and the patients they serve.

Looking Ahead

With a wealth of experience and a history of successful transformations, Paul Miele's addition to Accuray's executive team aims to set a robust foundation for the company's future. This is not simply about growth metrics but about driving innovation and impacting patient care positively—a mission that lies at the heart of Accuray's vision.